Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  Li, Yong ^a   Zheng, You Bing ^a   Zhao, Wei ^a   Liu, Bing ^a   Hu, Bao Shan ^a   He, Xu ^a   Huang, Jian Wen ^a   Lu, Li Gong ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Ablation; Hepatocellular carcinoma; Sorafenib; Therapy; Transarterial chemoembolization

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; EPIRUBICIN; HEMOGLOBIN; IODINATED POPPYSEED OIL; OXALIPLATIN; SORAFENIB; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; NICOTINAMIDE;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ARTICLE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPONATREMIA; LIVER CELL CARCINOMA; MALE; METABOLIC DISORDER; MIDDLE AGED; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPHIL COUNT; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PRURITUS; RADIOFREQUENCY ABLATION; RADIOFREQUENCY ABLATION DEVICE; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VOMITING; LIVER TUMOR; RETROSPECTIVE STUDY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 84883855857     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0730-5     Document Type: Article

References (23)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-76. (Pubitemid 46890874)
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-2.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429-42. (Pubitemid 36152543)
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
5. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61-74.
6. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762-73.
7. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453-9.
8. Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2013;139:653-9.
9. Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci. 2013;58:2107-13.
10. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-57.
11. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49:523-9.
12. Xu M, Xie XH, Xie XY, et al. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo. Acta Radiol. 2013;54:199-204.
13. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
14. Cho YK, Rhim H, Noh S. Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review. J Gastroenterol Hepatol. 2011;26:1354-60.
15. Han G, Yang J, Shao G, et al. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncol. 2013;9:403-10.
16. Cabrera R, Pannu DS, Caridi J, et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2011;34:205-13.
17. Zhao Y, Wang WJ, Guan S, et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol. 2013;24:1786-92.
18. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009;252:905-13.
19. Zhao M, Wang JP, Li W, et al. Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors. Zhonghua Yi Xue Za Zhi. 2011;91:1167-72.
20. Peng ZW, Chen MS. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma. Oncology-Basel. 2013;84(Suppl 1):40-3.
21. Bai W, Wang YJ, Zhao Y, et al. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J Dig Dis. 2013;14:181-90.
22. Svendsen MN, Werther K, Nielsen HJ, Kristjansen PE. VEGF and tumour angiogenesis. Impact of surgery, wound healing, inflammation and blood transfusion. Scand J Gastroenterol. 2002;37:373-9. (Pubitemid 34274318)
23. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10:2878-82. (Pubitemid 39303010)